REVISTA

Aposito medicado con lidocaína al 5% para el tratamiento del dolor neuropático periférico crónico: síndrome de dolor regional complejo y otras afeccio

Descripción: Aposito medicado con lidocaína al 5% como terapia complementaria para una serie de afecciones periféricas de dolor neuropático, incluido el SDRC

TITULO FUENTE ORIGINAL:

5% Lidocaine-medicated plaster for the treatment of chronic peripheral neuropathic pain: complex regional pain syndrome and other neuropathic conditions

AUTORES:

Calderón E, Calderón-Seoane ME, García-Hernández R, Torres LM

REVISTA ABREV.:

Journal of Pain Research

AÑO:

2016

REFERENCIA:

9:763-770

DOI:

10.2147/JPR.S113517

RESUMEN ORIGINAL:

OBJECTIVES:
Chronic neuropathic pain and chronic complex regional pain syndrome (CRPS), in particular, are debilitating and difficult-to-treat conditions that have a strong impact on patient's quality of life. The aim of this study was to evaluate the effectiveness of 5% lidocaine-medicated plaster as add-on therapy in patients with chronic peripheral neuropathic pain conditions,...
+ Leer más

OBJECTIVES:
Chronic neuropathic pain and chronic complex regional pain syndrome (CRPS), in particular, are debilitating and difficult-to-treat conditions that have a strong impact on patient's quality of life. The aim of this study was to evaluate the effectiveness of 5% lidocaine-medicated plaster as add-on therapy in patients with chronic peripheral neuropathic pain conditions, including CRPS.

PATIENTS AND METHODS:
This was a single-center, prospective, observational study set in a specialized pain unit of a tertiary hospital in Spain. A total of 56 patients with long-standing peripheral neuropathic pain, ten of them with CRPS, received 5% lidocaine-medicated plaster as add-on analgesic therapy for 6 months.

RESULTS:
After 6 months of treatment, a ≥50% reduction in pain intensity was attained by 75% of patients, as measured by numeric rating scale (NRS) for pain. The average NRS score was reduced by 61% (4.7 points), from a baseline mean score of 7.8 to an end point mean score of 3.1. Marked improvements were also observed in the CRPS group: six out of ten patients achieved a ≥50% reduction in NRS score, and the average NRS score for patients with CRPS was reduced by 51% (4.0 points), from a baseline mean score of 7.9 to an end point mean score of 3.9. The improvements in pain intensity were partially translated into a decrease in disability index and in anxiety levels.

CONCLUSION:
5% Lidocaine-medicated plaster may be useful as add-on therapy for a number of peripheral neuropathic pain conditions, including CRPS

- Leer menos

ENLACES DE INTERÉS

Enlace al pdf de acceso libre: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC[...]